Delving into the Latest Updates on IMP-13 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

IMP 13, IMP13

Target

USP1

Action

inhibitors

Mechanism

USP1 inhibitors(ubiquitin specific peptidase 1 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

IMPACT Therapeutics, Inc.

Active Organization

IMPACT Therapeutics, Inc.

Inactive Organization-

License Organization-

Drug Highest PhaseIND Application

First Approval Date-

Regulation-

Login to view timeline

Author: Guijarro-Sánchez, Paula ; Oviaño, Marina ; Velasco, David ; Alonso-García, Isaac ; Fernández-Pérez, Begoña ; Vallejo, Juan Andrés ; Ruedas-López, Alba ; Arca-Suárez, Jorge ; Lasarte-Monterrubio, Cristina ; Gato, Eva ; Fraile-Ribot, Pablo Arturo ; Beceiro, Alejandro ; Gutiérrez-Urbón, José María ; Bou, Germán ; Oliver, Antonio ; González-Bello, Concepción ; Vázquez-Ucha, Juan Carlos

Infections caused by ceftolozane-tazobactam and ceftazidime-avibactam-resistant P. aeruginosa infections are an emerging concern. We aimed to analyze the underlying ceftolozane-tazobactam and ceftazidime-avibactam resistance mechanisms in all multidrug-resistant or extensively drug-resistant (MDR/XDR) P. aeruginosa isolates recovered during 1 year (2020) from patients with a documented P. aeruginosa infection.

100 Deals associated with IMP-13

Login to view more data